An overview of gene therapy in head and neck cancer

Bali, Amit; Bali, Deepika; Sharma, Ashutosh

doi:10.4103/0971-6866.120811

Cited by 8 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many different genetic mutations found in HNSCC patients assist in tumor cell survival, invasiveness, and therapy resistance. Amid the most common altered genes, p53 has a high mutation frequency [ 60 , 61 ]. Gendicine, the first gene therapy approved for HNSCC, is based on an antitumor effect by restoring p53 function using an adenoviral vector delivery system.…”

Section: Therapeutic Approaches For Head and Neck Squamous Cell Carcinomamentioning

confidence: 99%

New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas

Porcheri

Mitsiadis

2021

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent types of cancer with a lethal outcome in half of the diagnosed cases. Mostly, HNSCC develops in the oral cavity, and its development is associated with tobacco and areca nut/betel quid usage, alcohol consumption, and HPV infection. Oral squamous cell carcinoma, as other head and neck cancers, presents a high degree of intratumor heterogeneity, which makes their treatment difficult, and directly correlates with drug resistance. Since the classical treatments for HNSCC oftentimes do not resolve the clinical picture, there is great need for novel therapeutic approaches, models for drug testing, and new drug delivery systems.

show abstract

Section: Therapeutic Approaches For Head and Neck Squamous Cell Carcinomamentioning

confidence: 99%

New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas

Porcheri

Mitsiadis

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Gene therapy is generally delivered locally and HNSCC is ideally suited for gene therapy because lesions are readily accessible for injection or application of the agent. Several genetic alterations of tumor suppressor genes have been reported in the head and neck cancer including mutation of TP53, the retinoblastoma gene, p16 (CDKN2A) and PTEN [53,116]. Since the high incidence of TP53 mutation (69.8%) [117] and the protein p53 plays an important role in cell cycle and in apoptosis, gene therapy approaches delivering p53 have been tested in HNSCC by direct injection of an adenoviral vector expressing wild-type p53 gene (Adp53), mostly in the USA and the People’s Republic of China [118].…”

Section: Competitive Environmentmentioning

confidence: 99%

Emerging drugs for head and neck cancer

Wen

Grandis

2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, with chemotherapy or radiation improves overall survival. However, the response rates to cetuximab are modest. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve outcome. Areas covered Current EGFR-targeted drugs under clinical development include mAbs and tyrosine kinase inhibitors. The modest efficacy of these drugs implicates intrinsic or acquired resistance. Novel molecular agents inhibiting alternative targets to overcome anti-EGFR resistance in HNSCC are under investigation. Gene therapy and immunotherapy are also promising strategies to improve efficacy and reduce toxicity. Expert opinion To date, only six drugs have been FDA-approved for the treatment of head and neck cancer. Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression of EGFR in HNSCC tumors, clinical responses are limited. Genetic and epigenetic characterization of HNSCC tumors, coupled with improved preclinical models, should facilitate the development of more effective drugs.

show abstract

“…While much headway has been made towards so-called "gene-therapy" for cancer treatment, ectopic replacement of tumour suppressor genes or RNA-interference mediated knock-down of oncogenes are still in the pre-clinical/early clinical stages of evaluation, and continued advancements in delivery methods will be necessary before such techniques can be applicable in the clinical arena 367 . As such, small molecule inhibitors of MTDH or downstream signaling pathway members might be more viable options.…”

Section: Clinical Implementationmentioning

confidence: 99%

The Role of MicroRNAs in Human Nasopharyngeal Carcinoma

Bruce

Hui

Waggot

et al. 2012

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Despite significant improvement in locoregional control in the contemporary era, nasopharyngeal carcinoma (NPC) patients still suffer from a significant risk of distant metastasis (DM). Thus, developing methods to better identify and treat NPC patients at risk of DM is of paramount importance. MicroRNAs (miRNAs) have been shown to provide insight into both the biology and clinical behaviour of human cancers; hence, this thesis aims to characterize both the First, I would like to express my deep gratitude to my supervisor and mentor, Fei-Fei Liu for her continuous scientific, personal and professional guidance. Her enthusiasm for scientific discovery and constant focus on using these discoveries to impact patient care are what gave me purpose and kept me engaged during the long hours of bench work and data analysis. Her extensive network of fellow researchers and physicians, and confidence in my abilities (even when I sometimes lacked the same confidence in myself) also provided me with the opportunity to participate in many exciting collaborations. In addition, I would like to thank the other members of my advisory committee, Lori Frappier and Laurie Ailles for their time and effort. Their thoughtful review of the progress of my project and valuable scientific advice was instrumental to my success as a PhD candidate. I would also like to acknowledge the members of the Liu Lab; past and present. In particular, Angela Hui who was my mentor and colleague in much of the work presented in this thesis. Her extensive knowledge of nasopharyngeal carcinoma, biospecimen analysis, and cell biology was invaluable as I navigated the waters of translational research. A special thanks also to

show abstract

An overview of gene therapy in head and neck cancer

Cited by 8 publications

References 49 publications

New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas

New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas

Emerging drugs for head and neck cancer

The Role of MicroRNAs in Human Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About